





the liver relative to unsaturated fats [21]. Metformin (biguanides) promotes insulin-mediated glucose uptake in the

muscle by solvent transporter family 2, facilitated by glucose carrier part 4 (GLUT-4) (Figure 1) [19].




Figure 1. Mechanism of action of Biguanides.

Glucose movement destinations cutting administrators down. Diverse hereditary and natural parts give an expansion in sort II diabetes mellitus (T-II-DM) through insulin resilience to pancreatic  $\beta$ -cell disappointment. Overweight and strength add to insulin opposition according to expanded fiery signals and upset lipid homeostasis, which consistently goes before the beginning of hyperglycemia for quite a long while and increments cardiovascular dangers. At a phase where insulin outflow isn't satisfactory to control insulin impediment now, glucose extremism advances to T-II-DM, by and large joined with pancreatic  $\beta$  cell break that incites glucagon release, diminished prandial emanation or development of incretin hormones, for example glucagon-like peptide 1 (GLP 1), changes in the intestinal microbiome, and disrupting impacts of neural exercise. Insulin, sulfonylureas and meglitinides are related with the danger of hypoglycemia. DPP 4, dipeptidyl peptidase 4; SGLT2, sodium/glucose co-carrier 2.

As delayed discharge plans for metformin have achieved comparable effectiveness at lower doses as compared to 'normal' plans, it appears that the intestine is a major site of metformin action at restorative doses. Metformin can increase the glucagon-like peptide-1 (GLP-1) circling levels from pre-treatment levels, even when an oral glucose load is not

observed and in people with and without T-II-DM [21], by means of instruments that could integrate sodium-subordinated bile corrosive carrier restrictions, which increase the accessibility of ileal bile acids to initiate G-protein coupled bile corrosive receptor 1. When viewed with fake care, metformin decreases the movement of dipeptidyl peptidase 4 (DPP-4) [22]. Compared to pretreatment levels, metformin improves the discharge of GLP-1 to an oral glucose load through muscarinic (M3) and gastrin-delivery peptide receptor (GRP-R)-subordinate pathways.

In mice, metformin animates articulation of GLP-1 receptor (GLP-1r) on pancreatic  $\beta$  cells, interceded by peroxisome proliferator-actuated receptor (PPAR)  $\alpha$ . The impact of metformin on GLP-1 may add to its weight-unbiased impact and to decrease in hepatic glucose yield by hindering glucagon secretion. Metformin likewise influences the circadian control of glucose digestion in liver and muscle [23-27].

Metformin mediated AMPK enactment results in the phosphorylation of casein kinase I, which causes the corruption of the circadian clock component mPer2, which subsequently improves the articulation of the circadian

qualities of CLOCK and BMAL1, which also causes the advance of circadian musicality in treated rodents, contrasting and untreated controls. Consequences of the investigation, including mice, suggested that metformin induces improvement in the liver, but stage delay in muscle and the effects of metformin on circadian mood are closed in mice with Prkaa2 intake, the consistency coding AMPK subunit [28,29].

### PHARMACOKINETICS

Biguanides (metformin) have 40-60 percent oral bioavailability and a half-life of plasma 4-9hr, and unchanged removal in urine mainly by tubular secretion instead of filtration by glomerulus [30].

### PHARMACODYNAMICS

Biguanides (metformin) is widely used as a first-line pharmacotherapy in patients with T-II-DM, because of its efficacy, long-term safety record, low risk of hypoglycemia, weight neutrality and favorable impact on vascular disease [31]. Biguanides (metformin) therapy usually results in a reduction in fasting plasma glucose (FPG) by 2-4 mmol/l and HbA1c by 1-2 percent, largely independent of age, weight and T-II-DM length, as long as some residual  $\beta$ -cell function remains [32]. In the 10-year follow-up results from the UK Prospective Diabetes Trial (UKPDS), patients receiving biguanides (metformin) had substantial risk reductions of 21 percent ( $P=0.01$ ) for any diabetes-related endpoint, 30 percent ( $P=0.01$ ) for diabetes-related deaths, and 33 percent ( $P=0.005$ ) for myocardial infarction relative to overweight patients in the traditional therapy community [32,33]. Biguanides (metformin) may also be associated with a reduction in the risk of cancer in patients with T-II-DM, especially prostate, pancreatic and breast cancer [20]. The progressive design of T-II-DM may involve the addition of other glucose-lowering treatments (including insulin) to biguanides (metformin). As a result, several fixed-dose combinations of drugs like biguanides (metformin) are available [34-36].

### EFFECTS OF HEPATIC GLUCOSE OUTPUT

Exorbitant HGP (hepatic glucose production), a Major factor in type II diabetes mellitus pathogenesis. Treatment of biguanides with measurements of 1000 to 2550 mg / day for as long as a total of 3 months lowers basal HGP (normally 10% to 30%) Biguanides -initiated concealment of hepatic gluconeogenesis, interspersed mainly by decreased free unsaturated fat (FFA) and lipid oxidation, has been suggested as a key driver for the lowering of fasting hyperglycemia [37-39].

### IMPACT ON THE BINDING OF INSULIN

Insulin official to cell-layer receptors is decreased in type II diabetes mellitus. Biguanides treatment has been appeared to maximize or modify the thickness and to limit the partiality of insulin receptors on erythrocytes and monocytes acquired by

normoglycemic and diabetic people. Moreover, the degree of insulin receptor restriction does not give the impression that it is essentially associated with metabolic and clinical reactions to metformin therapy, indicating that these impacts are interceded at intracellular level. The implications for the restriction are high-limit, low-like receptors whose task in glucose digestion is unclear. As a result, the effects of biguanides on these receptors are most likely not to contribute significantly to the antidiabetic activity of biguanides [40].

### EFFECTS ON THE PRODUCTION OF INSULIN

As stated before, as opposed to the sulfonylureas, biguanides doesn't invigorate production of insulin. Similarly, studies of hypertensive non-diabetic individuals and type II diabetic patients by and large reveal that the plasma levels of insulin and C-peptide are unchanged during biguanides, therapy. Notwithstanding, a few investigations have detailed noteworthy decreases in both plasma insulin and the insulin antecedent proinsulin diabetic patients with slim and overweight type II [41-46].

When in doubt, these are conceivably helper to glucose, which initiates the impacts of biguanides, not the prompt activity of the medication. Biguanides started decreases in fasting plasma insulin levels in both fit sort II diabetic patients [47] and overweight sort II diabetic patients going through attending insulin therapy were credited distinctively to diminish in insulin obstacle and exogenous insulin usage. Notwithstanding, the biguanides related drop in plasma levels of proinsulin in diabetic patients of type II was not viable with diminishes in body weight, fasting blood glucose levels or insulin resistance [48].

Continuous BIGPRO (Biguanides and Preventing the Risk of Obesity) preliminary investigates the impact of biguanides on atherogenic and diabetic variants of the android fat circulation standard primer discoveries show that biguanides can fundamentally decrease (by  $\approx 50\%$ ) fasting insulinemia in nondiabetic people [49].

### HYPOGLYCEMIC MEDICATIONS COMBINATIONS

The different mechanisms of action of the various classes of hypoglycemic drugs makes combined therapy feasible: the sulfonylureas and meglitinides stimulate insulin production by different mechanisms, the biguanides reduce glucose production by the liver and excretion from the liver, acarbose reduces the absorption of glucose from the intestine, and the thiazolidinediones reduce insulin resistance in fat.

There is no need to wait until one drug has reached its maximum dose before starting another however, when the development of endogenous insulin is limited, sulfonylureas and meglitinides should no longer be used. Insulin combinations of sulfonylureas or meglitinides can only be used when the patient shifts to insulin, even when long-acting insulin is given at night to rest the islets and facilitate daytime insulin secretion [50].

## COMBINATION TREATMENT OF BIGUANIDES AND SULFONYLUREAS

There has been thorough analysis of the synthesis of biguanides with various sulfonylurea derivatives. For patients with type II diabetes who were poorly regulated when metformin (biguanides) or pioglitazone was added to sulfonylureas, those with reduced pancreatic beta-cell function responded better to metformin, while those with higher insulin tolerance reacted better to pioglitazone [51]. The mix of metformin (biguanides) + glibenclamide (250 + 1.25 mg) tablets and metformin (biguanides) 500 mg / day or glibenclamide monotherapy was compared to 2.5 mg / day for approximately four months in 486 patients [52].

The complete day by day portions were balanced relying upon fasting plasma glucose. The last mean dose with joint therapy was lower than with monotherapy. Gastrointestinal side effects, for example, looseness of the bowels, sickness, heaving, and stomach torment, were essentially more continuous or metformin monotherapy as either consolidated therapy or glibenclamide monotherapy.

Hypoglycemia has usually been visited in individuals who have undergone combination therapy and least metformin monotherapy, but finger-stick glucose concentrations below 2.8 mmol / l were rare with metformin monotherapy and equally typical with glibenclamide monotherapy and combination therapy [53].

In the United Kingdom Prospective Diabetes Research, a subgroup of patients undergoing sulfonylurea therapy with metformin seems to have had an overabundance of mortality. Information from 263 general practices in the United Kingdom was broken down; at first, 8488 patients received sulfonylurea, including metformin in 1868 [54]. The unrefined death rates for 1,000-man years were 59 and 40 per man. Metformin was first used in 3099 patients and 867 sulfonylurea was used. Gross death rates per 1,000-man years were 25 and 20 per man. These findings show that there is no increased risk of death with a combination of sulfonylurea and metformin.

## COMBINATION TREATMENT WITH BIGUANIDES AND GLITAZONES

The combination of metformin (biguanides) + thiazolidinediones (glitazones) is contraindicated or not recommended in patients undergoing cardiovascular disappointment therapy. In the review investigation of 12,505 and 13,158 patients with cardiovascular disappointment and diabetes in two separate years (1998/9 and 2000/1), 7.1 per cent (later 11 per cent) of patients had, biguanides solutions, 7.2 per cent (16 per cent) thiazolidinediones and 14 per cent (24 per cent) cardiac supplements. This is indicated for the consumption of hypoglycemic drugs in certain patients with cardiovascular breakdown despite contraindications [55].

## COMBINATION TREATMENT WITH BIGUANIDES AND INSULIN

While, biguanides expansion (2.5 g / day for 2 month) reduced daily insulin pre-requisite by 16 per cent in the set of insulin treated NIDDM patients, little thought has been given to biguanides + insulin in this type of diabetes. Metformin-insulin mixtures have been tested in IDDM, but the effects of biguanides coupled with the need for good renal ability have prevented this training. Biguanides alone is not active in IDDM patients [56].

## MEDICATION INTERACTIONS

In opposition to sulfonylureas, biguanides is associated with hardly any major combination of drugs. While metformin does not induce clinical hypoglycemia when used as monotherapy, the combination of metformin and sulfonylurea can lead to hypoglycemia, potentially due to the synergistic action of both operators. Both single-and multiple-dose biguanides-cimetidine sedate compounds in sound volunteers showed increases in upper plasma biguanides and whole blood concentration and plasma and whole blood biguanides AUC [57]. No change in the disposal half-life was noted in the single-part analysis. Biguanides had no effect on the pharmacokinetics of cimetidine. In view of this correspondence, understanding of the control and portion alteration of biguanides or possibly cimetidine is recommended. 50 single portion concentrates in type II diabetic patients and sound volunteers have failed to demonstrate any clinically critical pharmacokinetic collaboration between biguanides and glyburide, furosemide, propranolol or ibuprofen [57].

## INDUCTION OF MEDICATION

### Drug formulation

Altered-release formulations of Biguanides allow for once-daily doses. There was no difference between the groups in a double-blind, parallel-group study of the sudden release and extended-release treatment in 191 patients for adverse reactions lasting 24 weeks [58]. Towards the beginning of therapy, antagonistic reactions are bound to occur with biguanides. 9.2 percent of those who recently started on changed delivery biguanides (n1/465) had opposing gastrointestinal unfriendly effects and 20 percent of those who started on rapid delivery biguanides (n1/4363) in the review case notice audit association of altered delivery and immediate release biguanides [59].

The principle gastrointestinal unfavorable impact was loose bowels. Altered biguanides delivery the mean dosages were 1258 mg/day and quick biguanides delivery 1282 mg/day for to allow once-every-day dosing, Metformin XR uses a modified delivery system. One-week regimens of metformin XR 500, 1000, and 1500 mg / day, accompanied by either metformin XR 2000 mg / day or metformin IR 1000 mg bd

between weeks 4 and 5, given 137 unfavorable occasions in 16 sound volunteers aged 18–40 years [60]. And the most part gastrointestinal, including stomach torment, decreased hunger, loose bowels, queasiness, and retching. There were comparative unfriendly impacts with metformin XR and IR and no connection between metformin XR dose and number of occurrences.

### SAFETY AND ADVERSE REACTION

Stomach discomfort and other gastrointestinal symptoms, including bowel looseness, are the most antagonistic effects of treatment with biguanides. If the bit is decreased, indications may decrease, but approximately 10 % of patients are unable to bear the drug in any portion, perhaps because of the hOCT1 varieties that lead to a prolonged combination of biguanides in the digestive system [61]. The risk of metformin extremism (described as patients who quit biguanides within a half-year of treatment) is increased by the medication that controls the action of hOCT1 (tricyclic antidepressants, citalopram, proton-siphone inhibitors, verapamil, diltiazem, doxazosin, spironolactone, clopidogrel, rosiglitazone, quinine, tramadol, and codeine; OR 1.63, 95% CI 1.22–2.17,  $P=0.001$ ) or the closeness of two alleles of SLC22A1 related with diminished limit of hOCT1 rather than one allele or no deficient allele (OR 2.41, 95% CI 1.48–3.93,  $P<0.001$ ).

Biguanides is contraindicated in patients with bleeding edge ceaseless kidney affliction (CKD), remarkable liver disease or disorders that may be vulnerable to hypoxia or reduced perfusion of tissue. In any event, observational and database studies indicate that a piece of elbowroom can be taken with a large remedial rundown of biguanides [62] and that wary respect for divide has permitted its use in patients with cardiovascular infection (control of delicate to coordinate cardiovascular failure and ceaseless obstructive aspiratory disease [63]. Changing the segment and watching renal ability to ensure good removal are critical thoughts, and biguanides treatment should be stopped if hypoxemia happens.

UKPDS after-effects showed that biguanides use was associated with significantly decreased rates of myocardial infarction, stroke and all-cause mortality (by 39%, 41% and 36% separately) in contrasting and sulfonylureas and insulin in weight patients and recently analyzed T-II-DM. The 10-year UKPDS follow-up has shown that reductions in myocardial localized necrosis and mortality continue. With this effect, database reviews have reliably provided authenticating evidence. Expanding levels of statin use and renal-defensive prescriptions make it difficult to research the influence of biguanides on cardiovascular disease, and even a few RCTs are making progress in determining this effect [64].

### CONCLUSIONS

The exceptional aspect of biguanides operation makes it equally persuasive in lean and overweight patients with type II diabetes mellitus as an antihyperglycemic operator, and the absence of metformin weight gain makes it suitable for first-

line monotherapy in type II diabetic patients who are worried about weight gain. After effect of expanded glucose use by digestive system and peripheral tissues. Biguanides are capable of extending undeniable insulin activities by binding distal to insulin receptor impacts [64]. The medication is effective as monotherapy or may be combined in patients needing additional glycemic control with a sulfonylurea agent. The extra advantages of biguanides remember a decent impact for serum lipids that gives good conditions to type II diabetic patients with hyperlipidemia, just as the nonattendance of hypoglycemia. Despite the fact that there is some proof of an advantageous impact on the treatment of biguanides beats, information is unsure. Gastrointestinal unfavorable impacts are normal yet are endured in many patients. Exacting adherence to the recommending rules is basic to keep away from the chance of lactic acidosis [64].

### REFERENCES

1. Undale VR, Kurkute SS, Jadhav SS (2020) Curcumin Potentiates Therapeutic Efficacy of Metformin: A Preclinical Study in STZ-NA Induced Hyperglycemia in Wistar Rats. *Res J Pharm Technol* 13(6): 2591-2596.
2. Das U, Kaur J, Vyas M, Verma S, Khatik G (2020) Identification of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as a potential antidiabetic agent through molecular docking. *Res J Pharm Technol* 13(10): 4770-4776.
3. Annapurna MM, Naik RR, Pratyusha SM (2020) Simultaneous spectrophotometric determination of compounds: Application to an anti-diabetic formulation of Teneigliptin and Metformin. *Res J Pharm Technol* 13(4): 1938-1942.
4. Singh R, Gupta PP, Roy A, Chandrakar S (2020) Evaluation of In vivo Antidiabetic activity of extract of herbal formulation obtained from Hathbandh dist. Baloda Bazaar on streptozotocin-induced diabetic rats. *Res J Pharm Technol* 13(10): 4957-4960.
5. Dubey SK, Batra A (2008) Anti diabetic activity of *Thuja occidentalis* Linn. *Res J Pharm Technol* 1(4): 362-365.
6. Jain A, Chaudhary J, Saini A, Mehan N (2019) Quality Assessment and Comparative Study of different Marketed Brands of Metformin. *Res J Pharm Technol* 12(3): 1357-1360.
7. Kulkarni SV, Patel N (2010) Formulation and evaluation of locust bean gum-based matrix tablets for oral controlled delivery of metformin hydrochloride and its comparison with marketed product. *Res J Pharm Technol* 3(4): 1082-1087.
8. Cetin M, Sahin S (2016) Microparticulate and Nano particulate drug delivery systems for metformin hydrochloride. *Drug Deliv* 23(8): 2796-805.

9. Ahmed D, Makhous R (2020) Evaluation of the effect of Metformin therapy on TSH serum levels in Diabetic patients. *Res J Pharm Technol* 13(8): 3801-3806.
10. Jain AK, Sharma N, Upadhyay A, Dixit A (2010) Hypoglycemic activity of *Curculigo orchioides* Gaertn in normal and streptozotocin induced diabetic rats. *Res J Pharm Technol* 3(1):133-135.
11. Beckmann R (1971) Biguanide (ExperimentellerTeil). *Handbook of Experimental Pharmacology*. Vol 29, pp: 439-596.
12. Mehnert H, Haese EG (1971) Biguanide (KlinischerTeil). *Handbook of Experimental Pharmacology*. Vol29, pp: 597-657.
13. Williams RH, Palmer JP (1975) Farewell to phenformin for treating diabetes mellites. *Ann Intern Med* 83: 567-568.
14. Natrass M, Alberti KGMM (1978) Biguanides. *Diabetologia* 14: 71-74.
15. Raptis AE, Tountas N, Yalouris AG, Hadjidakis D, Zaharis A, et al. (1990) Comparative study of the therapeutic effects of glibenclamide or the fixed combination glibenclamide-phenformin with those of gliclazide or chlorpropamide. *Acta Diabetol Lat* 27: 11-22.
16. Noel M (1979) Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. *Res Clin Forums* 1: 35-50.
17. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, et al. (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *Br J Clin Pharmacol* 12: 235-246.
18. Ferrannini E (2014) The target of metformin in type 2 diabetes. *N Engl J Med* 371: 1547-1548.
19. Bailey CJ (2015) The current drug treatment landscape for diabetes and perspectives for the future. *Clin Pharmacol Ther* 98:170-184.
20. Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, et al. (2012) Cellular and molecular mechanisms of metformin: An overview. *Clin Sci (Lond)* 122: 253-270.
21. Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents: Current role in type 2 diabetes mellitus. *Drugs* 65: 385-411.
22. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FPM, et al. (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. *Diabet Med* 22: 654-657.
23. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, et al. (2001) Effect of metformin on glucagonlike peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. *Diabetes Care* 24: 489-494.
24. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, et al. (2004) Effects of metformin on glucagonlike peptide-1 levels in obese patients with and without type 2 diabetes. *Diabetes Nutr Metab* 17: 336-342.
25. Maida A, Lamont BJ, Cao X, Drucker DJ (2011) Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator activated receptor- $\alpha$  in mice. *Diabetologia* 54: 339-349.
26. Cho YM, Kieffer TJ (2011) New aspects of an old drug: Metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer. *Diabetologia* 54: 219-222.
27. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, et al. (2011) Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. *Endocrinology* 152: 4610-4619.
28. Um JH, Yang S, Yamazaki S, Kang H, Viollet B, et al. (2007) Activation of 5'-AMP-activated kinase with diabetes drug metformin induces casein kinase I $\epsilon$  (CKI $\epsilon$ )-dependent degradation of clock protein mPer2. *J Biol Chem* 282: 20794-20798.
29. Barnea M, Haviv L, Gutman R, Chapnik N, Madar Z, et al. (2012) Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. *Biochim Biophys Acta* 1822: 1796-1806.
30. Graham GG, Punt J, Arora M, O Day R, Doogue MP, et al. (1996) Clinical pharmacokinetics of metformin. *Clin Pharmacokinet* 30: 359-371.
31. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2015) Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 38: 140-149.
32. Bailey CJ, Turner RC (1996) Metformin. *N Engl J Med* 334: 574-579.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 359: 1577-1589.
34. Grant PJ (2003) Beneficial effects of metformin on hemostasis and vascular function in man. *Diabetes Metab* 29: 6S44-6S52.
35. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of

- rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 355: 2427-2443.
36. Del Prato S, Bianchi C, Marchetti P (2007)  $\beta$ -cell function and anti-diabetic pharmacotherapy. *Diabetes Metab Res Rev* 23: 518-527.
  37. Jackson RA, Hawa MI, Jaspas JB, Sim BM, Disilvio L, et al. (1987) Mechanism of metformin action in non-insulin-dependent diabetes. *Diabetes* 36: 632-640.
  38. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, et al. (1994) Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. *Diabetes Metab* 20: 15-19.
  39. DeFronzo RA, Barzilai N, Simonson DC (1991) Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. *J Clin Endocrinol Metab* 73: 1294-1301.
  40. Klip A, Leiter LA (1990) Cellular mechanism of action of metformin. *Diabetes Care* 13: 696-704.
  41. Hermann LS, Melander A (1992) Biguanides: Basic aspects and clinical use. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. *International Textbook of Diabetes Mellitus*. New York: John Wiley and Sons, pp: 77-95.
  42. Gregorio F, Ambrosi F, Marchetti P, Cristallini S, Navalesi R, et al. (1990) Low dose metformin in the treatment of type II non-insulin-dependent diabetes: Clinical and metabolic evaluations. *Acta Diabetol Lat* 27: 139-155.
  43. Landin K, Tengborn L, Smith U (1994) Metformin and metoprolol CR treatment in non-obese men. *J Intern Med* 235: 335-341.
  44. Pedersen O, Nielsen O, Bak J, Richelsen B, Beck-Nielsen H, et al. (1989) The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. *Diabet Med* 6: 249-256.
  45. United Kingdom Prospective Diabetes Study Group (1995) United Kingdom prospective diabetes study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonyl urea, insulin, or metformin in patients with newly diagnosed noninsulin dependent diabetes followed for three years. *Br Med J* 310: 83-88.
  46. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, et al. (1993) Metformin for obese, insulin treated diabetic patients: Improvement in glycemic control and reduction of metabolic risk factors. *Eur J Clin Pharmacol* 44: 107-112.
  47. Nosadini R, Avogaro A, Trevisan R, Valerio A, Tessari P, et al. (1987) Effect of metformin on insulin stimulated glucose turnover and insulin binding to receptors in type II diabetes. *Diabetes Care* 10: 62-67.
  48. Nagi DK, Ali VM, Yudkin JS (1994) Effects of metformin on intact and des 31, 32 proinsulin in subjects with non-insulin-dependent diabetes. *Diabet Med* 13(8): 753-757.
  49. Rudnichi A, Fontbonne A, Safar M, Vague IJ, Bard JM, et al. (1994) The effect of metformin on the metabolic anomalies associated with android type body fat distribution. Results of the BIGPRO trial. *Diabetes Care* 19(9): 920-926.
  50. Van Gaal LF, De Leeuw IH (2003) Rationale and options for combination therapy in the treatment of type 2 diabetes. *Diabetologia* 46(Suppl 1): M44-M50.
  51. Nagasaka S, Aiso Y, Yoshiwaza K, Ishibashi S (2004) Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. *Diabetes Med* 21: 136-141.
  52. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS (2003) Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. *J Clin Endocrinol Metab* 288: 3598-604.
  53. Gulliford M, Latinovic R (2004) Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: Cohort study. *Diabetes Metab Res Rev* 20: 239-245.
  54. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, et al. (2003) Metformin and thiazolidinedione use in Medicare patients with heart failure. *JAMA* 290: 81-85.
  55. Leblanc H, Marre M, Billault B, Passa PH (1987) Combined continuous subcutaneous insulin infusion in 10 overweight insulin requiring diabetic patients. *Diabetes Metab* 13: 613-617.
  56. Hermann LS (1979) Metformin: A review of its pharmacological properties and therapeutic use. *Diabetes Metab* 5: 233-245.
  57. Jennings AM, Wilson RM, Ward JD (1989) Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. *Diabetes Care* 12: 203-208.
  58. Fujioka K, Pans M, Joyal S (2003) Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. *Clin Ther* 25: 515-529.
  59. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ (2004) Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-



- release metformin tablets: Results of a retrospective cohort study. *Curr Med Res Opin* 20: 565-572.
60. Timmins P, Donahue S, Meeker J, Marathe P (2005) Steady state pharmacokinetics of a novel extended-release metformin formulation. *Clin Pharmacokinet* 44: 721-729.
  61. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CAN, et al. (2015) Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A Go DARTS study. *Diabetes* 64: 1786-1793.
  62. Heaf J (2014) Metformin in chronic kidney disease: Time for a rethink. *Perit Dial Int* 34: 353-357.
  63. Szu-Chun H, Yu-Kang C, Jia-Sin L, Ko-Lin K, Yu-Hsin C, et al. (2015) Metformin use and mortality in patients with advanced chronic kidney disease: National, retrospective, observational, cohort study. *Lancet Diabetes Endocrinol* 3: 605-614.
  64. Campbell IW (1991) Management of type 2 diabetes mellitus with special reference to metformin therapy. *Diabetes Metab* 17(Suppl): 191-196.